Table 3. Baseline characteristics of p16-positive subjects, by laterality of radiation.
| Characteristic | Unilateral RT (n=53) | Bilateral RT (n=89) | p-value |
| Mean age at diagnosis | 55.2 | 56.0 | 0.65 |
| Gender | 0.09 | ||
| Male | 43 (81%) | 74 (83%) | |
| Female | 10 (19%) | 15 (17%) | |
| T Stage | < 0.01 | ||
| T1 | 22 (42%) | 22 (25%) | |
| T2 | 28 (53%) | 39 (44%) | |
| T3 | 3 (6%) | 21 (24%) | |
| T4 | 0 | 8 (8%) | |
| N Stage | < 0.01 | ||
| N0 | 15 (28%) | 11 (12%) | |
| N1 | 18 (34%) | 8 (9%) | |
| N2a | 7 (13%) | 9 (10%) | |
| N2b | 11 (21%) | 36 (40%) | |
| N2c | 0 | 12 (14%) | |
| N3 | 2 (4%) | 13 (15%) | |
| Stage | < 0.01 | ||
| I | 1 (2%) | 2 (2%) | |
| II | 13 (25%) | 5 (6%) | |
| III | 19 (36%) | 9 (10%) | |
| IVA | 18 (34%) | 60 (67%) | |
| IVB | 2 (4%) | 13 (15%) | |
| Smoking | 0.03 | ||
| Current/quit less than 1 year | 13 (25%) | 29 (33%) | |
| Former (quit more than 1 year) | 28 (53%) | 27 (30%) | |
| Never | 12 (23%) | 33 (37%) | |
| Radiation | |||
| < 60 Gy | 35 (66%) | 31 (35%) | < 0.01 |
| 61-70 Gy | 18 (34%) | 58 (65%) | |
| RT alone | 42 (79%) | 41 (46%) | <0.01 |
| CRT | 11 (21%) | 48 (54%) | |
| Chemotherapy | 0.30 | ||
| Cisplatin-based | 19 (91%) | 37 (77%) | |
| Carboplatin-based | 1 (9%) | 11 (23%) | |
| Surgery | 0.29 | ||
| None | 51 (96%) | 77 (87%) | |
| Primary resection | 0 | 1 (1%) | |
| Post-RT primary and UND | 0 | 1 (1%) | |
| Post-RT UND | 2 (4%) | 1 0 (11%) | |